Summary
Vertex Pharmaceuticals Inc. (VRTX) reported a significant net loss of $124.1 million for the third quarter of 2013, a substantial increase from the $57.5 million loss in the same period last year. This widened loss is primarily driven by a steep decline in product revenues, largely due to the diminishing sales of INCIVEK, its hepatitis C treatment. While KALYDECO, a cystic fibrosis drug, saw increased revenues, it was not enough to offset the decline in INCIVEK sales. The company also incurred significant research and development expenses, alongside restructuring charges related to workforce reductions and asset impairments, notably a $412.9 million charge for VX-222. Despite the widening net loss and declining INCIVEK revenue, Vertex Pharmaceuticals maintains a strong liquidity position with $1.4 billion in cash, cash equivalents, and marketable securities as of September 30, 2013. The company is strategically focusing its investments on its cystic fibrosis pipeline, particularly on expanding KALYDECO's label and advancing the combination of ivacaftor and lumacaftor, and on developing all-oral, interferon-free regimens for HCV. Investors should monitor the progress of these key development programs and the impact of the ongoing strategic restructuring on future financial performance.
Financial Highlights
49 data points| Revenue | $221.70M |
| Cost of Revenue | $20.05M |
| Gross Profit | $201.65M |
| R&D Expenses | $219.44M |
| SG&A Expenses | $86.43M |
| Operating Expenses | $345.26M |
| Operating Income | -$123.56M |
| Net Income | -$124.13M |
| EPS (Basic) | $-0.54 |
| EPS (Diluted) | $-0.54 |
| Shares Outstanding (Basic) | 230.50M |
| Shares Outstanding (Diluted) | 230.50M |
Key Highlights
- 1Significant increase in net loss attributable to Vertex, reaching $124.1 million in Q3 2013 compared to $57.5 million in Q3 2012.
- 2Product revenues declined 39% year-over-year to $186.7 million, driven by a 66% drop in INCIVEK sales, partially offset by a 106% increase in KALYDECO sales.
- 3Research and development expenses increased by 14% to $228.6 million in Q3 2013, reflecting continued investment in pipeline development.
- 4A substantial $412.9 million intangible asset impairment charge for VX-222 was recorded, significantly impacting the year-to-date results.
- 5Restructuring expenses increased significantly due to a strategic workforce reduction announced in October 2013, impacting approximately 15% of the workforce.
- 6The company maintains a strong liquidity position with $1.4 billion in cash, cash equivalents, and marketable securities as of September 30, 2013.
- 7Vertex is prioritizing development efforts on its cystic fibrosis programs and all-oral HCV regimens, signaling a strategic shift away from INCIVEK.